Argenica's Phase 2 Trial Updates

Argenica Therapeutics (ASX:AGN) has announced positive safety outcomes in its Phase 2 clinical trial of ARG-007, a neuroprotective peptide for acute ischemic stroke patients. The Data Safety Monitoring Board recommended the continuation of the trial without modifications after reviewing safety data from the first 46 patients. To date, 58 patients have been dosed, marking 63% completion across 7 hospital sites with no serious adverse events reported.

Trial Advancements and Future Plans

Argenica Therapeutics is making significant progress in its Phase 2 clinical trial of ARG-007, aimed at protecting brain tissue in acute ischemic stroke patients. With 63% of patient dosing completed and no serious adverse events reported, the company demonstrates both the safety of ARG-007 and the efficiency of trial operations. The trial is expected to conclude dosing by the end of Q2 2025, with topline data anticipated shortly after. Argenica remains focused on advancing its therapeutic candidate, which has shown promise in pre-clinical models and a completed Phase 1 trial.

Executive Insights on Clinical Trial Progress

We are pleased with the progress of our Phase 2 clinical trial of ARG-007, having achieved 63% recruitment and dosing of patients, and with the DSMB's recognition of our clean safety profile,' said Dr. Liz Dallimore, Managing Director.